BiotechTube
Samsara Therapeutics

Samsara Therapeutics

Oxford, United Kingdom· Est.
samsaratherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37M

Overview

Samsara Therapeutics is a private, pre-clinical biotech pioneering a novel approach to treating neurodegenerative diseases through pharmacological activation of autophagy. The company has built a phenotypic screening platform using patient-derived iPSCs to discover and optimize small molecule autophagy activators, with a pipeline targeting ALS, Parkinson's, and CMT1A. Backed by a $25M Series A led by Apollo Health Ventures and endorsements from major patient advocacy foundations, Samsara is advancing multiple programs toward IND-enabling studies.

Neurodegenerative Diseases

Technology Platform

Phenotypic screening platform for autophagy activators using high-throughput, cell-based assays in disease-relevant, patient-derived induced pluripotent stem cells (iPSCs).

Funding History

1
Total raised:$37M
Seed$37M

Opportunities

The high unmet need in neurodegenerative diseases like ALS and Parkinson's presents a massive market opportunity for a first disease-modifying therapy based on autophagy activation.
Success in one indication would strongly validate the platform for expansion into other age-related proteinopathies.
Partnerships with patient foundations provide non-dilutive funding, validation, and direct access to patient-centric research networks.

Risk Factors

The core scientific risk is the challenge of safely and effectively modulating the complex autophagy pathway with a drug for chronic human diseases.
The company faces significant translational risk in moving from pre-clinical models to human efficacy.
As a pre-revenue biotech, it is also dependent on raising additional capital to fund expensive clinical trials.

Competitive Landscape

The field of autophagy modulation for neurodegeneration is emerging but competitive, with several academic and biotech entities exploring similar concepts. Samsara differentiates itself with its patient-derived iPSC screening platform and a pipeline spanning multiple diseases and autophagy mechanisms. They compete with both other modality approaches (e.g., ASOs, gene therapy) and large pharma companies developing treatments for the same indications.

More companies in Small Molecule Drugs →More companies in United Kingdom →